Table S1. Clinical and demographic characteristics of symptomatic COVID-19 patients.

| Characteristics                                      | Total (n = 1116) |
|------------------------------------------------------|------------------|
| Median age (IQR), yr                                 | 50 (37–61)       |
| Women                                                | 402 (36.0)       |
| Ethnicity                                            |                  |
| East Asia                                            | 1033 (92.6)      |
| Southeast Asia                                       | 42 (3.8)         |
| South Asia                                           | 26 (2.3)         |
| South America                                        | 14 (1.3)         |
| Unknown                                              | 1 (0.1)          |
| Median body weight (IQR), kg                         | 67 (57–77)       |
| Median body mass index (IQR), kg/m²                  | 24.1 (21.6–27.2) |
| Residence before the index admission                 |                  |
| Home                                                 | 1105 (99.0)      |
| Nursing care facility or other hospital              | 11 (1.0)         |
| Activities of daily living at admission              |                  |
| Independent                                          | 1088 (97.5)      |
| Partially dependent                                  | 22 (2.0)         |
| Dependent                                            | 6 (0.5)          |
| Vaccination for COVID-19                             |                  |
| None                                                 | 1024 (91.8)      |
| Once                                                 | 68 (6.1)         |
| Twice                                                | 24 (2.2)         |
| Mean Charlson comorbidity index score (SD)           | 0.4 (0.8)        |
| Current smoker                                       | 288 (25.8)       |
| Regular alcohol drinkera                             | 288 (25.9)       |

*aAmong 1,112 patients because data on four patients were missing.

IQR, interquartile range.
Table S2. Medical history and venous thromboembolism risk of symptomatic COVID-19 patients.

| Characteristics                              | Total (n = 1116) |
|----------------------------------------------|-----------------|
| Past medical history                         |                 |
| Ischemic heart disease                       | 17 (1.5)        |
| Heart failure                                | 11 (1.0)        |
| Stroke                                       | 32 (2.9)        |
| Dementia                                     | 16 (1.4)        |
| Liver cirrhosis                              | 3 (0.3)         |
| Diabetes mellitus                            | 134 (12.0)      |
| Hypertension                                 | 306 (27.4)      |
| Dyslipidemia                                 | 221 (19.8)      |
| Chronic kidney disease                       | 10 (0.9)        |
| Dialysis                                     | 0 (0.0)         |
| COPD/asthma                                  | 88 (7.9)        |
| Atrial fibrillation                          | 20 (1.8)        |
| Median number of regular medications (IQR)   | 0 (0–3)         |
| Regular medications at admission             |                 |
| Immunosuppression drugs                      | 16 (1.4)        |
| Antiplatelets                                | 48 (4.3)        |
| Anticoagulants                               | 23 (2.1)        |
| Antipsychotics                               | 17 (1.5)        |
| Venous thromboembolism risk                  |                 |
| Active cancer                                | 8 (0.7)         |
| Previous venous thromboembolism              | 3 (0.3)         |
| Reduced mobility                             | 29 (2.6)        |
| Thrombophilic condition                      | 0 (0.0)         |
| Recent trauma or surgery (within one month)  | 3 (0.3)         |
| Elderly age (more or 70 years old)           | 178 (16.0)      |
| Heart or respiratory failure                 | 102 (9.1)       |
| Acute myocardial infarction or ischemic stroke| 0 (0.0)        |
| Acute infection or rheumatologic disorder    | 1116 (100.0)    |
| Obesity                                      | 138 (12.4)      |
| Ongoing hormonal treatment                   | 6 (0.5)         |
| Padua score                                  |                 |
| Median (IQR)                                 | 1 (1–2)         |
| Mean (SD) | 1.5 (1.0) |
|----------|-----------|
| Four or more points, n (%) | 43 (3.9) |

COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; IQR, interquartile range; SD, standard deviation.
**Table S3.** Clinical characteristics of symptomatic COVID-19 patients.

| Characteristics                                                                 | Total (n = 1116) |
|---------------------------------------------------------------------------------|------------------|
| Median days to admission from symptom onset (IQR)                               | 5 (3–7)          |
| Median duration of fever from onset until discharge, days (IQR)                  | 4 (1–8)          |
| Symptoms at admission                                                           |                  |
| Fever                                                                           | 690 (61.8)       |
| Cough                                                                           | 649 (58.2)       |
| Malaise                                                                         | 507 (45.4)       |
| Headache                                                                        | 323 (28.9)       |
| Sore throat                                                                     | 301 (27.0)       |
| Dysosmia                                                                        | 215 (19.3)       |
| Dysgeusia                                                                       | 206 (18.5)       |
| Arthralgia                                                                      | 181 (16.2)       |
| Diarrhea                                                                        | 174 (15.6)       |
| Dyspnea                                                                         | 165 (14.8)       |
| Sputum                                                                          | 157 (14.1)       |
| Rhinorrhea                                                                      | 145 (13.0)       |
| Severity at admission                                                           |                  |
| Presymptomatic                                                                  | 26 (2.3)         |
| Mild                                                                             | 758 (67.9)       |
| Moderate                                                                        | 230 (20.6)       |
| Severe                                                                           | 98 (8.8)         |
| Critical                                                                        | 4 (0.4)          |
| The worst severity during hospitalization                                       |                  |
| Mild                                                                             | 543 (48.7)       |
| Moderate                                                                        | 315 (28.2)       |
| Severe                                                                           | 204 (18.3)       |
| Critical                                                                        | 54 (4.8)         |
| Saturated oxygen concentration at admission                                     |                  |
| Median (IQR)                                                                     | 97 (96–98)       |
| Mean (SD)                                                                        | 96.3 (2.3)       |
| Oxygen therapy                                                                   |                  |
| At admission                                                                     | 32 (2.9)         |
| During hospitalization                                                           | 220 (19.7)       |
| Duration of oxygen therapy during hospitalization                                |                  |
|                                | Median (IQR) | Mean (SD)   |
|--------------------------------|--------------|-------------|
| Presence of pneumonia<sup>a</sup> | 0 (0–0)      | 1.0 (3.0)   |
| Blood tests                    | 567 (50.8)   |             |
| Computed tomography of chest   | 123 (11.0)   |             |
| Peripheral or central access for fluid infusion<sup>b</sup> | 30 (2.7)     |             |
| Treatment                      | 88 (7.9)     |             |
| Remdesivir                     | 0 (0.0)      |             |
| Dexamethasone                   | 248 (22.2)   |             |
| Tocilizumab                     | 38 (3.4)     |             |
| Casirivimab/imdevimab           | 86 (7.7)     |             |
| Duration of hospital stay, days |                                    |
| Median (IQR)                   | 6 (3–8)      |             |
| Mean (SD)                      | 6.9 (7.6)    |             |
| In-hospital death              | 9 (0.8)      |             |
| Destination from discharge     |                                    |
| Home                           | 715 (64.1)   |             |
| Hotel for isolation            | 327 (29.3)   |             |
| Hospital for rehabilitation    | 12 (1.1)     |             |
| Nursing care institution       | 4 (0.4)      |             |
| Follow-up days from presentation|                                    |
| Median (IQR)                   | 6 (4–9)      |             |
| Mean (SD)                      | 11.5 (27.1)  |             |

<sup>a</sup>Defined as clinical symptoms and crackles on physical examination or infiltration on chest imaging.

<sup>b</sup>This excluded peripheral venous access for infusion of casirivimab/imdevimab or tocilizumab.

IQR, interquartile range; SD, standard deviation.